Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)

Trial Profile

An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2018

At a glance

  • Drugs AAV-REP1 (Primary)
  • Indications Choroideraemia
  • Focus Therapeutic Use
  • Acronyms REGENERATE; REGENERATE
  • Most Recent Events

    • 04 Oct 2018 Status changed from active, no longer recruiting to recruiting.
    • 09 Mar 2018 New trial record
    • 13 Dec 2017 Status changed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top